TherapeuticsMD Q2 net income $545K vs loss last year; license revenue up to $1.0M

TherapeuticsMD, Inc.

2025-Q2 EPS reported -$0.01 revenue$1,345,000

Net income from continuing operations $545K ($0.05/share) vs net loss of -$1.05M (-$0.09) in Q2 2024.
License revenue $1.0M, up $0.7M from $234K, driven by changes in Mayne License Agreement product sales.
Total operating expenses fell 45.5% to $1.647M, primarily due to no impairment in current quarter.
Cash and equivalents $6.1M as of June 30, 2025; company continues strategic alternatives review.
No timetable set for strategic transaction outcome; no assurance of any deal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.